Physician profile
Barbara Jane Chamness
NPI 1366951972
$14,510.31
in general payments reported to CMS, 2019-2025
45 companies · $4,573 in 2025
The $4,573 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,283 · 2022: $2,912 · 2023: $2,495 · 2024: $3,246 · 2025: $4,573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,204 · Consulting Fee: $900 · Education: $211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,203.98 |
| Consulting Fee | $900.00 |
| Education | $210.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,135.21 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,982.38 | 2021-2025 | Fasenra, Breztri, Imfinzi |
| Regeneron Healthcare Solutions, INC. | $1,523.31 | 2022-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,466.47 | 2021-2025 | Ofev, Jascayd, Spiriva Respimat |
| Genzyme Corporation | $1,063.27 | 2021-2025 | |
| United Therapeutics Corporation | $827.17 | 2021-2025 | Tyvaso, Orenitram, Remodulin |
| Grifols USA, LLC | $755.06 | 2021-2025 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $470.50 | 2021-2025 | Glassia, Hyqvia, Aralast |
| Actelion Pharmaceuticals US, INC. | $467.71 | 2021-2025 | Opsumit, Uptravi, Opsynvi |
| Bayer Healthcare Pharmaceuticals INC. | $374.39 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $325.85 | 2023-2025 | Winrevair, Zerbaxa, Recarbrio |
| Insmed, INC. | $281.10 | 2022-2025 | Arikayce, Brinsupri |
| Inspire Medical Systems, INC. | $270.43 | 2025 | Inspire |
| Philips North America LLC | $229.94 | 2021-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Amgen INC. | $213.04 | 2021-2025 | Tezspire |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $199.90 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $195.06 | 2021-2024 | |
| Abbvie INC. | $145.72 | 2022-2024 | |
| Boston Scientific Corporation | $136.50 | 2025 | Watchman Flx |
| Verona Pharma, INC. | $132.95 | 2025 | Ohtuvayre |
| Mylan Specialty L.P. | $131.36 | 2023-2024 | Yupelri |
| Jazz Pharmaceuticals INC. | $122.25 | 2022-2025 | |
| Baxter Healthcare | $120.10 | 2022-2024 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Astellas Pharma US INC | $109.00 | 2022-2025 | Cresemba |
| Avadel Cns Pharmaceuticals, LLC | $79.78 | 2023-2025 | Lumryz |
| Viatris Specialty LLC | $79.72 | 2025 | Yupelri |
| Alexion Pharmaceuticals, INC. | $73.06 | 2023-2024 | Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $62.50 | 2021-2022 | |
| Pfizer INC. | $59.42 | 2021-2024 | |
| Lilly USA, LLC | $54.23 | 2025 | Zepbound |
| Harmony Biosciences LLC | $52.72 | 2022-2023 | Wakix |
| Vifor Pharma, INC. | $50.63 | 2024 | Veltassa |
| Mallinckrodt Hospital Products INC. | $48.86 | 2022 | |
| Electromed, INC. | $41.49 | 2023-2024 | Smartvest |
| La Jolla Pharmaceutical Company | $39.37 | 2024 | Xacduro, Giapreza |
| Aerin Medical INC. | $25.78 | 2024 | |
| Inogen, INC. | $22.11 | 2022 | |
| Melinta Therapeutics, LLC | $21.07 | 2023 | Vabomere |
| Axsome Therapeutics, INC. | $20.95 | 2025 | Sunosi |
| Bard Peripheral Vascular, INC. | $20.06 | 2025 | Pleurx |
| Gilead Sciences, INC. | $18.61 | 2022 | |
| Scpharmaceuticals INC. | $17.35 | 2025 | |
| Adma Biomanufacturing LLC | $17.14 | 2021 | |
| Angiodynamics, INC. | $14.05 | 2025 | Angiovac |
| Olympus America INC. | $12.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Chamness listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.